• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Travalert(®)给药辅助工具对青光眼患者药物治疗依从性及生活质量的影响]

[The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients].

作者信息

Sánchez-Pulgarín M, Martínez-de-la-Casa J M, Escalada A, Sáenz-Francés F, García-Feijoó J, García Sánchez J

机构信息

Departamento de Glaucoma, Hospital Clínico San Carlos, Madrid, España.

出版信息

Arch Soc Esp Oftalmol. 2011 Sep;86(9):282-6. doi: 10.1016/j.oftal.2011.04.011. Epub 2011 Jul 22.

DOI:10.1016/j.oftal.2011.04.011
PMID:21893261
Abstract

PURPOSE

To study compliance in the medical treatment of glaucoma, its possible association with other factors, and quality of life of patients with glaucoma.

MATERIAL AND METHODS

Longitudinal prospective study of 60 patients with ocular hypertension or glaucoma who were treated with travoprost, or with a fixed combination of travoprost/timolol nightly. All subjects were given a Travalert(®) dosing aid and were reviewed after one and four months. Strict and relative compliance data were collected on each visit. The relationship between compliance and other variables was studied using univariate analysis. To analyse quality of life, patients were given self-assessment STAI anxiety questionnaires after the first and last visits.

RESULTS

Relative compliance for the four months was significantly greater than the strict compliance (P=.001). In the group of least compliance the number of patients on treatment with combination therapy was significantly higher than those on monotherapy. In the lost cases, the number of men was significantly higher than women. No association was found in the other variables. The anxiety was similar to that in the normal population.

CONCLUSIONS

Compliance is very important in the treatment of glaucoma, and our study provides objective data through the use of Travalert dosing aid with relative compliances of 70%. Patients with combined therapies have lower compliance than those on monotherapy.

摘要

目的

研究青光眼药物治疗的依从性、其与其他因素的可能关联以及青光眼患者的生活质量。

材料与方法

对60例高眼压症或青光眼患者进行纵向前瞻性研究,这些患者接受曲伏前列素治疗,或每晚使用曲伏前列素/噻吗洛尔固定复方制剂治疗。所有受试者均使用Travalert®给药辅助工具,并在1个月和4个月后进行复查。每次就诊时收集严格依从性和相对依从性数据。使用单变量分析研究依从性与其他变量之间的关系。为分析生活质量,在首次和末次就诊后让患者填写自我评估的STAI焦虑问卷。

结果

四个月的相对依从性显著高于严格依从性(P = 0.001)。在依从性最低的组中,接受联合治疗的患者数量显著高于接受单一疗法的患者。在失访病例中,男性数量显著高于女性。在其他变量中未发现关联。焦虑情况与正常人群相似。

结论

依从性在青光眼治疗中非常重要,我们的研究通过使用Travalert给药辅助工具提供了客观数据,相对依从率为70%。联合治疗的患者依从性低于单一疗法的患者。

相似文献

1
[The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients].[Travalert(®)给药辅助工具对青光眼患者药物治疗依从性及生活质量的影响]
Arch Soc Esp Oftalmol. 2011 Sep;86(9):282-6. doi: 10.1016/j.oftal.2011.04.011. Epub 2011 Jul 22.
2
Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination.使用 Travatan 给药辅助装置监测青光眼患者的用药依从性。一项为期 6 个月的研究比较了使用 0.004% travoprost 患者和使用 0.004% travoprost/0.5% timolol 固定组合的患者。
Expert Opin Pharmacother. 2010 Mar;11(4):499-504. doi: 10.1517/14656561003601994.
3
Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.0.004%曲伏前列素/0.5%噻吗洛尔复方滴眼液每日一次治疗开角型青光眼或高眼压症的疗效与安全性
Am J Ophthalmol. 2005 Aug;140(2):242-50. doi: 10.1016/j.ajo.2005.02.058.
4
Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.通过电子方式监测使用特拉万给药辅助装置的青光眼局部用药依从性的研究。
Ophthalmology. 2009 Feb;116(2):191-9. doi: 10.1016/j.ophtha.2008.09.004. Epub 2008 Dec 12.
5
A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.一项为期6周的双盲平行组研究,比较0.004%曲伏前列素与0.005%拉坦前列素/0.5%噻吗洛尔治疗原发性开角型青光眼或高眼压症患者的疗效和安全性。
Clin Ther. 2006 Mar;28(3):332-9. doi: 10.1016/j.clinthera.2006.03.001.
6
Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.评估青光眼药物疗效的24小时眼压研究的荟萃分析。
Ophthalmology. 2008 Jul;115(7):1117-1122.e1. doi: 10.1016/j.ophtha.2007.10.004. Epub 2008 Feb 20.
7
The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.0.004%曲伏前列素/0.5%噻吗洛尔固定复方滴眼液的安全性和有效性。
Am J Ophthalmol. 2005 Jul;140(1):1-7. doi: 10.1016/j.ajo.2005.02.043.
8
Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.电子监测的青光眼患者滴眼剂依从性差的危险因素。
Ophthalmology. 2009 Jun;116(6):1097-105. doi: 10.1016/j.ophtha.2009.01.021. Epub 2009 Apr 19.
9
Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.在青光眼患者中,使用曲伏前列素/噻吗洛尔固定复方制剂降低眼压,联合或不联合布林佐胺辅助治疗。
Curr Med Res Opin. 2008 Jun;24(6):1755-61. doi: 10.1185/03007990802159273. Epub 2008 May 13.
10
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.一项随机、研究者设盲的4周研究,比较0.5%马来酸噻吗洛尔、1%布林佐胺和0.2%酒石酸溴莫尼定作为0.004%曲伏前列素辅助治疗药物,用于治疗原发性开角型青光眼或高眼压症成人患者的疗效。
Clin Ther. 2006 Apr;28(4):552-9. doi: 10.1016/j.clinthera.2006.04.007.

引用本文的文献

1
A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study.一种用于评估患者对规定用药方案依从性的新型滴眼剂应用监测器:一项试点研究。
Eye (Lond). 2015 Oct;29(10):1383-91. doi: 10.1038/eye.2015.155. Epub 2015 Sep 11.
2
Interventions for improving adherence to ocular hypotensive therapy.改善眼压降低治疗依从性的干预措施。
Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD006132. doi: 10.1002/14651858.CD006132.pub3.